1. Successful mobilization of peripheral blood stem cells in children with cancer using plerixafor (Mozobil™) and granulocyte-colony stimulating factor
- Author
-
Dragan G. Bobev, Boryana E. Avramova, Maya N. Yordanova, and Dobrin Konstantinov
- Subjects
Oncology ,Male ,medicine.medical_specialty ,Benzylamines ,Adolescent ,Pharmaceutical Science ,Antigens, CD34 ,G-CSF ,Cyclams ,Transplantation, Autologous ,children ,stem cells ,Heterocyclic Compounds ,Internal medicine ,Neoplasms ,Drug Discovery ,Granulocyte Colony-Stimulating Factor ,medicine ,Autologous transplantation ,Humans ,Leukapheresis ,Child ,mobilization ,Hematopoietic Stem Cell Mobilization ,Original Research ,Pharmacology ,Peripheral Blood Stem Cell Transplantation ,Drug Design, Development and Therapy ,Mobilization ,business.industry ,Plerixafor ,plerixafor ,Granulocyte colony-stimulating factor ,Blood Cell Count ,Transplantation ,Treatment Outcome ,Immunology ,Stem cell ,business ,medicine.drug - Abstract
Boryana E Avramova, Maya N Yordanova, Dobrin N Konstantinov, Dragan G BobevSpecialized Hospital for Treatment of Children with Onco-Haematological Diseases, Sofia, BulgariaAbstract: This paper describes the successful mobilization of peripheral blood stem cells for autologous transplantation in three children with malignant diseases by using plerixafor (Mozobil™; Genzyme Corporation, Cambridge, MA) and granulocyte-colony stimulating factor (G-CSF) after failed previous mobilizations. A median sixfold increase in the number of circulating CD34+ cells after plerixafor treatment as compared with the baseline level was observed. An optimal CD34+ cell count for transplantation with one or two leukapheresis sessions was achieved. Mobilization using plerixafor was found to be safe with no adverse events. Therefore, the combination of G-CSF and plerixafor in children results in effective increases in peripheral CD34+ cell counts and reduces the risk of mobilization failure.Keywords: stem cells, mobilization, plerixafor, children, G-CSF 
- Published
- 2011